NeuroThera Targets FDA Orphan Drug Status for Tourette Syndrome Treatment
Event summary
- NeuroThera Labs, a SciSparc subsidiary, is pursuing FDA Orphan Drug Designation for SCI-110, a cannabinoid-based treatment for adult Tourette Syndrome.
- The company has engaged RK Strategies, a government and public affairs firm, to strengthen its U.S. market position and visibility among key federal stakeholders.
- SCI-110 is currently in Phase IIb clinical trials across three international sites, with early results showing a 21% average tic reduction.
- The drug combines dronabinol and palmitoylethanolamide (PEA) in a single oral dosage form, targeting both tic reduction and associated comorbid symptoms.
The big picture
NeuroThera's push for Orphan Drug Designation underscores the growing interest in cannabinoid-based treatments for neuropsychiatric disorders. The engagement of RK Strategies signals a strategic shift toward proactive policy engagement, a critical move as the company navigates the complex regulatory landscape for rare disease therapies. With limited effective treatments currently available for adult Tourette Syndrome, SCI-110's potential to address both tics and comorbid symptoms positions it as a key asset in NeuroThera's pipeline.
What we're watching
- Regulatory Momentum
- Whether NeuroThera can secure FDA Orphan Drug Designation, which would materially strengthen SCI-110's market profile and accelerate development.
- Clinical Validation
- The pace at which Phase IIb trial results will confirm SCI-110's efficacy and safety in adult Tourette Syndrome patients.
- Market Access Strategy
- How RK Strategies' lobbying efforts will shape policy and long-term commercial success for SCI-110 in the U.S.
Related topics